tranexamic acid | sciencenewsnet.in

Breaking News

Survey of U.S. Parents Highlights Need for More Awareness About Newborn Screening, Cystic Fibrosis and What to Do if Results are Abnormal

American Association of Immunologists (AAI) Introduces New Brand Identity

Stony coral tissue loss disease is shifting the ecological balance of Caribbean reefs

Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

May is Mental Health Awareness Month. Experts and Patients Available for Interviews on Trending Issues

ChatGPT can be helpful for Black women’s self-education about HIV, PrEP

Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies for lung cancer — and cannabis and alcohol use in patients

A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss

Mexican researchers have found that people who avoid going to psychologists choose the most violent suicide methods

Genetics, not lack of oxygen, causes cerebral palsy in quarter of cases

06 May, 2024

Tranexamic acid may lower heterotopic ossification risk after elbow trauma surgery

June 21, 2023 sarah JonasResearch Results

For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO) – a common complication of abnormal bone formation, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

Anti-bleeding drug is safe for ‘high-risk’ patients undergoing hip fracture surgery

May 3, 2022 sarah JonasResearch Results

Tranexamic acid (TXA) – a medication given to reduce the risk of bleeding during some orthopaedic surgical procedures – can be safely used in patients with intertrochanteric (IT) hip fractures who are at high risk of blood clot-related complications, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.